Skip to main content

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.

  • Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 2:30 p.m. ET
  • Jefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 8:00 a.m. GMT

A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

Additionally, management will attend the J.P. Morgan Equity Opportunities Forum on Wednesday, November 13, 2024.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  247.38
+1.09 (0.44%)
AAPL  259.37
+0.33 (0.13%)
AMD  203.17
-1.51 (-0.74%)
BAC  55.85
-0.33 (-0.59%)
GOOG  329.14
+3.13 (0.96%)
META  653.06
+7.00 (1.08%)
MSFT  479.28
+1.17 (0.24%)
NVDA  184.86
-0.18 (-0.10%)
ORCL  198.52
+9.37 (4.95%)
TSLA  445.01
+9.21 (2.11%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.